company background image
KNE logo

Kane Biotech TSXV:KNE Stock Report

Last Price

CA$0.10

Market Cap

CA$13.8m

7D

0%

1Y

17.6%

Updated

26 Dec, 2024

Data

Company Financials

Kane Biotech Inc.

TSXV:KNE Stock Report

Market Cap: CA$13.8m

KNE Stock Overview

A biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. More details

KNE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Risk Analysis

Negative shareholders equity

Earnings have declined by 16.5% per year over past 5 years

Does not have a meaningful market cap (CA$14M)

Does not have meaningful revenue (CA$2M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Kane Biotech Inc. Competitors

COSCIENS Biopharma

TSX:CSCI

CA$11.8m

Medicure

TSXV:MPH

CA$9.3m

StageZero Life Sciences

TSX:SZLS

CA$4.9m

IBEX Technologies

TSXV:IBT

CA$35.3m

Price History & Performance

Summary of share price highs, lows and changes for Kane Biotech
Historical stock prices
Current Share PriceCA$0.10
52 Week HighCA$0.17
52 Week LowCA$0.07
Beta0.50
1 Month Change-13.04%
3 Month Change-23.08%
1 Year Change17.65%
3 Year Change-35.48%
5 Year Change-28.57%
Change since IPO-94.29%

Recent News & Updates

Recent updates

Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt

Nov 05
Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt

Is Kane Biotech (CVE:KNE) A Risky Investment?

Jul 14
Is Kane Biotech (CVE:KNE) A Risky Investment?

Is Kane Biotech (CVE:KNE) A Risky Investment?

Mar 27
Is Kane Biotech (CVE:KNE) A Risky Investment?

Shareholder Returns

KNECA BiotechsCA Market
7D0%0.6%1.7%
1Y17.6%5.5%16.1%

Return vs Industry: KNE exceeded the Canadian Biotechs industry which returned 12.5% over the past year.

Return vs Market: KNE exceeded the Canadian Market which returned 16.3% over the past year.

Price Volatility

Is KNE's price volatile compared to industry and market?
KNE volatility
KNE Average Weekly Movement12.6%
Biotechs Industry Average Movement13.7%
Market Average Movement8.1%
10% most volatile stocks in CA Market17.4%
10% least volatile stocks in CA Market3.0%

Stable Share Price: KNE has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: KNE's weekly volatility (13%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aMarc Edwardskanebiotech.com

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.

Kane Biotech Inc. Fundamentals Summary

How do Kane Biotech's earnings and revenue compare to its market cap?
KNE fundamental statistics
Market capCA$13.75m
Earnings (TTM)-CA$4.91m
Revenue (TTM)CA$2.01m

6.8x

P/S Ratio

-2.8x

P/E Ratio

Is KNE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KNE income statement (TTM)
RevenueCA$2.01m
Cost of RevenueCA$1.02m
Gross ProfitCA$993.60k
Other ExpensesCA$5.90m
Earnings-CA$4.91m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.036
Gross Margin49.36%
Net Profit Margin-243.98%
Debt/Equity Ratio-201.8%

How did KNE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 23:37
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kane Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution